Open AccessCOVID-19 vaccine landscape
Author(s) -
Suranjith L. Seneviratne,
Umesh Jayarajah,
Visula Abeysuriya,
A Rahman,
Kamani Wanigasuriya
Publication year - 2020
Publication title -
journal of the ceylon college of physicians
Language(s) - English
Resource type - Journals
ISSN - 2448-9514
DOI - 10.4038/jccp.v51i2.7906
Subject(s) - ceylon , audience measurement , medicine , sri lanka , medical journal , covid-19 , multidisciplinary approach , family medicine , alternative medicine , medical education , socioeconomics , disease , tanzania , infectious disease (medical specialty) , political science , law , history , pathology , ancient history , sociology
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is currently pandemic, and as of 15th November 2020, there have been 53.7 million confirmed cases worldwide and around 1.3 million deaths. The availability of an effective vaccine is the best long-term answer to the current COVID-19 pandemic. More than 210 candidate vaccines have come into development since the start of the pandemic. Eleven vaccines (ten of them specifically directed against SARS-CoV-2) have entered phase 3 clinical trials. Five of these vaccines have also been approved for early or limited use. This review outlines information on the current COVID-19 vaccine pipeline, discusses the pros and cons of different vaccine delivery systems and the steps involved in getting a safe and effective vaccine to the global population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom